Sunshine Novo announced that net profit attributable to owners of the parent company for the first half year of 2026 is -149.718 million yuan to -299.436 million yuan, a decrease of 145 million yuan to 160 million yuan compared with the same period last year, and a year-on-year decrease of 111.53% to 123.06%. Net profit after deducting non-recurring profit and loss is estimated to be -149.704 million yuan to -299.408 million yuan, and non-net profit after deducting 120 million yuan for the same period last year, a year-on-year decrease of 112.51% to 125.02%. The main reasons for the change in performance from profit to loss are: Innovative Pharmaceutical's external licensing cooperation business was affected by the industry and R&D cycle, and no large-scale BD business revenue was recorded in the current period; the pharmacy business was affected by collection policies and market competition, and orders and revenue declined year-on-year; and equity incentive amortization expenses increased year-on-year. The performance forecast data for this period has not been audited by a certified public accountant.

Sunshine Novo announced that net profit attributable to owners of the parent company for the first half year of 2026 is -149.718 million yuan to -299.436 million yuan, a decrease of 145 million yuan to 160 million yuan compared with the same period last year, and a year-on-year decrease of 111.53% to 123.06%. Net profit after deducting non-recurring profit and loss is estimated to be -149.704 million yuan to -299.408 million yuan, and non-net profit after deducting 120 million yuan for the same period last year, a year-on-year decrease of 112.51% to 125.02%. The main reasons for the change in performance from profit to loss are: Innovative Pharmaceutical's external licensing cooperation business was affected by the industry and R&D cycle, and no large-scale BD business revenue was recorded in the current period; the pharmacy business was affected by collection policies and market competition, and orders and revenue declined year-on-year; and equity incentive amortization expenses increased year-on-year. The performance forecast data for this period has not been audited by a certified public accountant.